HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical...

46
HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty

Transcript of HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical...

Page 1: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

HYPERPARATHYROIDISM

Hasan Aydın M.D.Endocrinology and Metabolism

Yeditepe University Medical Faculty

Page 2: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Hyperparathyroidism

A clinical syndrome characterized by

– ↑ PTH,

– PTH induced bone resorption

– Hypercalcemia

Page 3: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Types of Hyperparathyroidism

- Primary

- Secondary

- Tertiary

Page 4: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Primary Hyperparathyroidism

Page 5: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Primary Hyperparathyroidism

• Excessive, relatively uncontrolled secretion of PTH

• One or more hyperfunctioning parathyroid glands.

• Hypercalcemia, the biochemical hallmark

• Most patients today are relatively asymptomatic.

• Symptoms remarkably varied and vague.

Page 6: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Epidemiology

• Overall incidence is 42 in 100,000

• Incidence increases with age

• Most patients with sporadic primary

hyperparathyroidism are postmenopausal

women with an average age of 55 years

• Female to male ratio is 2-3:1

Page 7: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Etiology and Pathogenesis• Primary hyperparathyroidism is caused by

…..Parathyroid adenoma – 80%

…..Parathyroid hyperplasia – 15%

…..Parathyroid carcinoma – 1-2%

…..Approximately 10% are caused by “double adenoma”

• It can occur as part of at least three familial endocrinopathies

…..MEN 1

…..MEN 2A

…..Isolated familial hyperparathyroidism

Page 8: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Manifestations

• Renal

• Skeletal

• Gastrointestinal

• Neurologic-Neuromuscular

• Other

Page 9: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Symptoms and Signs

• Renal – hypercalciuria– nephrolithiasis– nephrocalcinosis– polyuria and polydipsia– renal insufficiency

• Neuromuscular – weakness– myalgia

Page 10: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Symptoms and Signs

Neurologic and psychiatric

- Memory loss - Confusion

- Depression - Lethargy

- Psychosis - Fatigue

- Paresthesias

Skeletal- Bone pain- Osteoporosis- Pathologic fractures- Bone cysts/brown tumors- Arthralgias- Chondrocalcinosis - Pseudogout and gout- Subperiosteal skeletal

resorption

Page 11: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Symptoms and Signs

• Peptic ulcer

– Zollinger-Ellison Syndrome ( MEN 1)

• Chronic pancreatitis

Page 12: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Other Manifestations

• Polyuria, polydipsia, constipation

• ECG changes (shortened Q-T )

• Band keratopathy, subconjunctival deposits

• Pruritus

• Ectopic calcifications (lungs, kidneys, skin, arteries)

• Hypertension

Page 13: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Hyperparathyroid Bone Disease

• Elevation of the alkaline phosphatase level

• Osteitis fibrosa cystica

• Subperiosteal resorption of cortical bone (phalanges)

• A salt-and-pepper appearance (in the skull)

• Bone cyst or brown tumors (jaw)

• Loss of the lamina dura of the teeth

• Osteoporosis (predominant loss of cortical bone)

Page 14: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.
Page 15: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.
Page 16: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Osteitis Fibrosa Cystica

Page 17: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Classical Phrase

Page 18: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Laboratory Findings

• Hypercalcemia is universal (>10.6 mg/dL)

• Serum phosphorus is low normal (<3.5 mg/dl) or

low (<2.5 mg/dl)

• Mild hyperchloremic metabolic acidosis

• PTH is elevated or high normal

• Alkaline phosphatase may be increased

Page 19: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Work-Up

• Rule out lithium or thiazide use

• Wrist, spine and hip DEXA

• Consider IVP or CT to evaluate for kidney stones

• Ionized calcium versus serum calcium—the debate rages on….

Page 20: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Differential Diagnosis• Due to increased serum PTH

– Primary and ''tertiary'' hyperparathyroidism– Nonhematologic malignant neoplasms

• Not due to increased serum PTH – Drug-induced (thiazide, furosemide, vitamin D, calcium,

vitamin A, lithium) – Granulomatous (sarcoidosis, tuberculosis, berylliosis)– Genetic (familial hypocalciuric hypercalcemia) – Immobilization – Idiopathic– Nonhematologic malignant neoplasms – Malignant hematologic diseases – Nonparathyroid endocrine disease (Addison's disease,

hyper and hypothyroidism)

Page 21: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Differential Diagnosis of Osteitis Fibrosa Cystica

• Paget’s disease of bone• Osteoporosis• Osteomalacia• Malignant diseases• Polyostotic fibrous dysplasia• Secondary hyperparathyrodism• Pseudohypoparathyroidism

Page 22: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Differential Diagnosis of Nephrolithiasis/Nephrocalcinosis

• Gout

• Hyperoxaluria

• Renal tubular acidosis

• Pyelonephritis

Page 23: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Treatment

• Definitive treatment is surgical parathyroidectomy

• Cure rate for adenomas >95% (less for hyperplasia)

• No value in pre-op studies to localize parathyroid tumors

• The only localization study needed is to locate an experienced

parathyroid surgeon

• No definitive medical therapy for hyperparathyroidism

Page 24: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

In the asymptomatic patient, who should undergo

surgery?

Page 25: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Indications for Surgery

• Overt clinical manifastations of primary hyperparathyroidism

– Radiographic nephrolithiasis or documented renal stones

– Reduced creatinine clearance (not otherwise explained)

– Radiographically evident hyperparathyroid bone disease

– Classical hyperparathyroid neuromuscular disease

– Symptoms attributable to hypercalcemia per se

– Previous episode of life threatening hypercalcemia

• Serum Ca concentration >12 mg/dL

• Low or declining bone mineral density

– >2 SD below age/sex matched controls (any site) or

– Vertebral osteopenia or– Declining vertebral bone mineral

density• Age younger than 50 years• Uncertain prospect for successful

monitoring

– Patient requests surgery– Consistent followup seems unikely– Coexistent illness that may contribute

to or confound detection of, disease progression

Page 26: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Other Considerations in Surgical Referral

• Neuropsychological abnormalities

– Several studies document improvement in HRQL after parathroidectomy

– Studies on neurobehavioral abnormalities have reported less consistent results with parathyroidectomy

• Cardiovascular abnormalities

– Symptomatic patients suffer from increased cardiovascular mortality before and after treatment

– Asymptomatic primary HPT is associated with LVH; some studies suggest this is reversible with parathyroidectomy

– Primary HPT patients have increased calcifications of mitral and aortic valve

• Perimenopausal women

– Asymptomatic primary HPT associated with increased bone turnover, reduced bone mineral density and higher risk for fractures

Page 27: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Pre-Operative Imaging

• High-resolution ultrasound– Sensitivity 65-85% for

adenoma; 30-90% for enlarged gland

– Results suboptimal in pts with multinodular thyroid disease, pts with short thick neck, ectopic glands (15-20%)

– May be useful in detecting sestamibi scan negative adenomas

• CT with contrast/thin section– Sensitivity of 46-87%– Good for ectopic glands in the

chest

• MRI– Sensitivity of 65-80%

– Good for ectopic glands

• Sestamibi

– 85-95% accurate in localizing adenoma in primary HPT

• Sestamibi-SPECT– Sensitivity 60% for enlarged gland

and 98% for solitary adenomas

Page 28: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Ultrasonographic Localization

Page 29: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Traditional Sestamibi Sestamibi-SPECT

Scintigraphy Images

Page 30: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

MRI Localization

Page 31: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Medical Management Primary HPT

• Bisphosphonates

– Studies have shown increase in lumbar spine and femoral neck

mineral density

• Calcimimetic agents (Cinacalcet)

– For intractable case of primary HPT

• Estrogen

– Dose required is high

• SERMs

– Reduction in serum calcium and markers of bone turnover after 4

weeks

Page 32: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Medical Treatment

Chronic moderate (12-15 mg/dL) hypercalcemia

– The drug of first choice for most patients is pamidronate

disodium. This is a biphosphanate drug that acts by

inhibiting osteoclastic bone resorption. The initial dose is

60-90 mg by intravenous infusion over 4-24 hours.

– Glucocorticoids-(hypercalcemia associated with

hematologic malignancies)

Page 33: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Medical Treatment

• Mithramycin- inhibition of bone resorption, (hematologic and

solid malignant disorders).

• Phosphate- lncreases in serum phosphorus above 5 mg/dL

should be avoided because of the danger of inducing

extraskeletal calcifications.

• Calcitonin-4-8 IU/kg

• Estrogen

• Other agents-- and -adrenergic blockers and cimetidine

Page 34: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Medical Treatment

Acute severe (> 15 mg/dL) hypercalcemia-.

a. Hospitalization-(immobilization may increase serum calcium

in some patients)

b. Calcium restriction

c. Reduction of digitalis

d. Hydration and diuretics- 4-6 L of isotonic saline IV+

furosemide 20-100 mg every 1-2 hours or ethacrynic acid 10-

40 mg every 1-2 hours

Page 35: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Maintenance Regimen

• Furosemide ( 40-160 mg/d orally) or ethacrynic acid (50-200

mg/d orally),

• Sodium chloride tab (400-600 mEq/d orally)

• At least 3 L of fluid per day

• Other drugs-

(1) Indomethacin-

(2) Mithramycin-

Page 36: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Treatment Categories

Criteria Preferred Treatment

1. One or more of the following: Surgical removal of

• Serum calcium > 11 mg/dl. parathyroid lesion

• Osteitis fibrosa cystica.

• Metabolically active nephrolithiasis

• Decreased renal function.

• Intractable peptic ulcer.

• Pancreatitis.

• Serious psychiatric disease.

• Severe hypertension.

Page 37: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Treatment Categories

• Unsuccessful surgery , or recurrence with manifestations; noted in category 1

• Serum calcium < 11 mg/dl.• Abnormal serum iPTH• Absence of manifestations noted in

category 1

• Surgery contraindicated.

• Surgical removal of parathyroid lesion; preoperative localization may be indicated

• Surgical removal of parathyroid lesion or medical management

• Medical management for hypercalcemia and nephrolithiasis prevention

Page 38: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Extent of Parathyroidectomy

Number of Glands Involved Procedure

All 4 Removal of 3 glands and all but 35-

50 mg of the fourth gland

Two or 3 Removal of all but half of a normal

gland; suture tagging of

remaining half.

One Removal of involved gland;

identification of remaining glands

(often by biopsy)

Page 39: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Ectopic Parathyroids

• In several studies the abnormal parathyroid glands were found

in the following sites.

– 30 to 54 percent were in the neck.

– 16 to 34 percent were in the mediastinum.

– 14 to 39 percent were retro-esophageal.

– 5 percent were in the aortic arch area.

– 8 percent were in the upper cervical area.

– A few were in the carotid sheath.

Page 40: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Secondary HPT

• Clinical presentation– Usually asymptomatic

• Diagnosis– Elevated PTH in the

setting of low or normal serum calcium is diagnostic

– If phosphorous is elevated, cause is renal

– If phosphorous is low, other causes of vit D deficiency should be sought

• Prevention

– Vit D replacement

– Phosphorus binders

• Treatment

– Medical

• Calcimimetic agents

– Surgical

• Considered in cases of refractory severe hypercalcemia, severe bone disease, severe pruritis, calciphylaxis, severe myopathy

Page 41: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Secondary Hyperparathyroidism of Chronic Renal Failure

• Associated with prolonged stimulation of the parathyroid

glands by chronic decreases in the concentration of ionic

calcium in the blood.

• Serum iPTH progressively increases as glomerular filtration

rate decreases below 40 ml/min.

• Increases in serum phosphorus concentrations at this same

level of GFR (40 mU/min)

Page 42: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Secondary Hyperparathyroidism of Chronic Renal Failure

Page 43: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Major Causes of Chronic Hypocalcemia in Renal Failure

• Dietary deficiency of vitamin D or calcium.

• Decreased intestinal absorption of vitamin D or calcium due to primary small bowel disease, short bowel syndrome, and postgastrectomy syndrome.

• Drugs that cause rickets or osteomalacia such as phenytoin, phenobarbital, cholestyramine, and laxatives.

• States of tissue resistance to vitamin D.

• Excessive intake of inorganic phosphate compounds.

• Pseudohypoparathyroidism .

• Severe hypomagnesemia.

• Chronic renal failure.

Page 44: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

Tertiary Hyperparathyroidism

– Develops in patients with long-standing secondary hyperparathyroidism, which stimulates the growth of an autonomous adenoma.

– A clue to the diagnosis of tertiary hyperparathyroidism is intractable hypercalcemia and/or an inability to control osteomalacia despite vitamin D therapy.

Surgical Referral- calcium- phosphate product > 70- severe bone disease and pain -intractable pruritus- extensive soft tissue calcification

with tumoral calcinosis -calciphylaxis

Page 45: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

In Conclusion

• Primary hyperparathyroidism is mostly caused by an

adenoma

• Most of the patient asymptomatic

• Definitive treatment with surgery

• Differentiated from secondary and tertiary

hyperparathyroidism

Page 46: HYPERPARATHYROIDISM Hasan Aydın M.D. Endocrinology and Metabolism Yeditepe University Medical Faculty.

T h a n k Y o u